Canada’s biotech stocks sizzled in the first quarter as they racked up impressive gains. The Burrill Canadian Biotech Index jumped 12 percent during the period. This is good news for the sector, which has languished for over three years. Low valuations have hampered the ability of public biotech companies to raise capital. The improving capital markets in Canada and the United States have helped bolster Toronto’s main stock index— the Toronto Stock Exchange’s S&P/TSX Composite Index—improving 3.5 percent during March and 2.5 percent for the quarter.
Click here to view the entire report
